Patients with recurrent glioblastoma (rGBM) are commonly treated with anti-angiogenic agents such as bevacizumab (BEV), but not all benefit from this therapy. We examined whether MR spectroscopic imaging (MRSI) of myo-inositol (mI) could distinguish short-term survivors from longer term survivors (>9 month). We scanned twenty-two rGBM patients with MRSI at baseline prior to bevacizumab-based therapy, as well as 1-2 days, 4 weeks, 6-8 weeks and 16 weeks after treatment. We found that low tumoral myo-inositol normalized by creatine (Cr) on the contralateral site (mI/c-Cr) prior to and during anti-angiogenic therapy is predictive of poor survival.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords